Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).
H. Schmoll
No relevant relationships to disclose
P. M. Hoff
Consultant or Advisory Role - AstraZeneca
J. D. Robertson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
L. Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. Morgan
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
D. Wilson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. M. Jürgensmeier
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca